|
|
|
|
 |
Ardea Biosciences Announces Upcoming Corporate Meetings |
| 5/14/2008 @ 5:32 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Ardea Biosciences, Inc. (NASDAQ:RDEA) today announced that the Company will present at the JMP Securities Seventh Annual Research Conference. Additionally, Ardea will be hosting a live webcast and conference call of their Annual Shareholder Meeting.
JMP Securities Conference
Presenter: Christopher W. Krueger, Senior Vice President and Chief
Business Officer
Date: Wednesday, May 21, 2008
Time: 11:30 a.m. Pacific Time
Location: The Ritz-Carlton, San Francisco
Webcast: www.wsw.com/webcast/jmp6/rdea/
Annual Shareholder Meeting
Ardea Biosciences' Annual Shareholder Meeting is scheduled for Thursday, May 22, at 9:30 a.m. Pacific Time and will be webcast. To participate by telephone, please dial 877-440-5804 from the U.S. and Canada or +1- 719-325-4854 for international callers. In addition, the live conference call is being webcast and can be accessed on the "News & Events" page of the Company's website at www.ardeabio.com/. A replay will also be available on Ardea's website for 14 days and by telephone through May 31, 2008. In the U.S. and Canada, please dial 888-203-1112 or +1- 719-457-0820 for international callers. For telephonic replay, please enter passcode 9342491 when prompted.
About Ardea Biosciences
Ardea Biosciences, Inc. of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment of HIV in a human micro-dose pharmacokinetic study and have selected it as a development candidate. We are also investigating RDEA806 for the treatment of gout. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers for the treatment of inflammatory diseases. We have evaluated our second generation MEK inhibitor, RDEA436, for the treatment of cancer and inflammatory diseases in a human micro-dose pharmacokinetic study, and have selected it as a development candidate. In addition to the foregoing clinical programs, we are investigating other drug candidates in earlier stages of preclinical development and discovery. |
| BioTech / BioMedical / Medical |
|
|
| |
| Tuesday, July 8, 2008 |
 |
|
International Stem Cell Corporation Announces Collaboration with Michigan State University to Study Parthenogenetic Stem Cells Posted 7:47 AM PST
FDA Grants Invitrogen Premarket Approval of Breast Cancer Test Posted 7:42 AM PST
|
| |
| Monday, July 7, 2008 |
|
|
Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV Posted 3:06 PM PST
AutoGenomics INFINITI Analyzer Receives Artistic Design Award Posted 6:35 AM PST
|
| |
| Wednesday, July 2, 2008 |
|
|
PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc. Posted 6:37 AM PST
Sequenom Launches iSEQ Application Posted 6:36 AM PST
Sequenom Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares Posted 6:36 AM PST
PURE Bioscience Strengthens Pharmaceutical Development Program Posted 6:33 AM PST
MicroIslet Provides Safety and Efficacy Data Update; No Adverse Events Attributable To MicroIslet-P In Animal Models Posted 6:31 AM PST
|
| |
| Tuesday, July 1, 2008 |
|
|
Metabasis to Present at the Collins Stewart 4th Annual Growth Conference Posted 4:34 PM PST
ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor Posted 1:35 PM PST
The Wellcome Trust Case Control Consortium (WTCCC) Selects Illumina Infinium High-Density (HD) DNA Analysis Products to Study 90,000 Samples Posted 8:04 AM PST
Aethlon Medical Announces Second HIV/AIDS Treatment Site Posted 8:03 AM PST
|
| |
| Monday, June 30, 2008 |
|
|
Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial Posted 3:11 PM PST
Invitrogen and the Génome Québec and Montreal Heart Institute Pharmacogenomics Centre Announce Collaboration to Advance Pharmacogenomics Research Posted 2:52 PM PST
Burnham Institute Researchers Link Early Stem Cell Mutation to Autism Posted 2:51 PM PST
SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 Posted 6:46 AM PST
Cardium Announces Follow-On Direct Investment by Institutional Investor Posted 6:41 AM PST
Early Results from Ongoing Clinical Study of Hepatitis C Vaccine Delivered by Inovio Biomedical’s Electroporation System Show Increased T-Cell Responses and Reduced Viral Loads Posted 6:31 AM PST
|
| |
| Wednesday, June 25, 2008 |
|
|
$6 Million Grant from NIH Advances Vical RapidResponse DNA Vaccine Platform Posted 8:55 AM PST
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing Posted 8:49 AM PST
Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients Posted 8:49 AM PST
International Stem Cell Corporation Cuts a Deal with BioTime, Inc., and Embryome Sciences, Inc., to Provide Unique Human Stem Cell Lines for Research Use Posted 8:08 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
